Wellmarker Bio Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 78
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 26

Wellmarker Bio General Information

Description

Developer of anticancer drugs designed to treat cancer patients. The company's drugs have biomarkers that predict therapeutic response, enabling healthcare providers to cure their patients and improve their lives.

Contact Information

Website
www.wmbio.co
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 7th floor
  • 155 Songpa-daero, Songpa-gu
  • Seoul, 05855
  • South Korea
+82 00-0000-0000

Wellmarker Bio Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Wellmarker Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 000.00 Completed Profitable
5. Later Stage VC (Series C) 01-Aug-2021 000.00 000.00 Completed Profitable
4. Early Stage VC (Series B) 08-Jul-2019 00.000 0000 Completed Profitable
3. Early Stage VC (Series A) 08-Oct-2018 000.00 000.00 Completed Pre-Clinical Trials
2. Seed Round 01-Apr-2018 $4.34M $4.34M Completed Pre-Clinical Trials
1. Corporate 27-Dec-2016 $2.11K $2.11K 00.000 Completed Startup
To view Wellmarker Bio’s complete valuation and funding history, request access »

Wellmarker Bio Patents

  • 20

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Wellmarker Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3819300-A4 Biomarker-based therapeutic composition Pending 06-Sep-2019 0000000000 0
EP-3819300-A1 Biomarker-based therapeutic composition Pending 06-Sep-2019 0000000000
JP-6955630-B2 Thienopyridine derivative and pharmaceutical composition containing it Active 08-Mar-2018 000000000
JP-2021500378-A Thienopyridine derivative and pharmaceutical composition containing it Granted 08-Mar-2018 0000000000
US-20210317133-A1 Thienopyridine derivatives and pharmaceutical composition comprising same Pending 08-Mar-2018 A61P35/00
To view Wellmarker Bio’s complete patent history, request access »

Wellmarker Bio Executive Team (1)

Name Title Board Seat Contact Info
Jin Dong-Hoon Co-Founder & Co-Chief Executive Officer
To view Wellmarker Bio’s complete executive team members history, request access »

Wellmarker Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Wellmarker Bio Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Ebest Investment & Securities Investment Bank Minority 000 0000 000000 0
Elohim Partners Venture Capital Minority 000 0000 000000 0
G2G Private Equity Venture Capital Minority 000 0000 000000 0
Lead Compass Investment Venture Capital Minority 000 0000 000000 0
Seoul Investment Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 26 investors. Get the full list »

Ready to get started?

Request a free trial